Abstract
Background:
Pertussis is an endemic respiratory tract infection caused by Bordetella pertussis that may affect all individuals from infants to older adults. Pertussis incidence in adults is often underreported and in various countries, including the United Kingdom (UK), there are evidence gaps on pertussis-associated economic burden in the older adult population. We aimed to quantify the economic burden of pertussis in adults aged ≥50 years in the UK.
Methods:
A cost-of-illness study was conducted to estimate the cost of pertussis from a societal perspective. We utilized a sum diagnosis cost approach in which costs related to infection with pertussis were included. Medical, patient, and indirect costs were calculated individually and combined to calculate total costs. A framework was developed to assess costs for consecutive age groups from 50–54 years of age to ≥85 years of age. Sensitivity and scenario analyses were used to assess analysis uncertainty.
Results:
The base-case analysis estimated the total annual economic burden of pertussis to be approximately £238 million (M). This comprised approximately £159 M in indirect costs, £66 M in medical costs, and £13 M in patient costs. Costs for the age group 55–59 years had the highest impact on the economic burden, with approximately £79 M in total annual costs. Visits to general practitioners and nurses were the largest contributors to medical costs (∼£37 M) followed by inpatient visits (∼£21 M). Transportation costs (∼£10 M) were the major patient costs. Productivity loss (∼£71 M) and leisure time loss (∼£72 M) had comparable contributions to annual indirect costs. Sensitivity and scenario analyses suggested that incidence rates, indirect costs, and underreporting estimates had the highest impact on outcomes.
Conclusion:
Total cost of pertussis in the UK among adults ≥50 years of age is substantial and highest for adults 55–59 years of age. Indirect costs were the main contributors to the economic burden.
Original language | English |
---|---|
Pages (from-to) | 6991-6998 |
Number of pages | 8 |
Journal | Vaccine |
Volume | 41 |
Issue number | 47 |
Early online date | 14 Oct 2023 |
DOIs | |
Publication status | Published - 13 Nov 2023 |
Bibliographical note
Funding:GlaxoSmithKline Biologicals SA funded the study (study identifier:
VEO-000220) and was involved in all stages of study conduct, including
analysis of the data. GlaxoSmithKline Biologicals SA also took in charge
all costs associated with the development and publication of this
manuscript.
Publisher Copyright:
© 2023 GSK